PKG plus routine assessment is associated with lower total costs compared to routine assessment (£141,950 versus £159,312) and improved quality adjusted life years (7.88 versus 7.61), resulting in an incremental cost-effectiveness ratio of -£64,978.99 and a net monetary benefit of £22,706.37 using a £20,000 threshold.
Management of PD involves monitoring and evaluation of symptoms to assess disease progression and ensure appropriate treatment choice. Adding the PKG to standard monitoring allows for improved and objective identification of PD motor symptoms which can be used in clinical decision making to improve patient outcomes.
More here: PubMed abstract
Our work with the World Economic Forum is published
We are super proud to have been involved in writing this White Paper with the World Economic Forum looking at how global sharing of data on rare diseases could provide benefits to diagnosis, management and treatment, clinical trials and personal well-being.